Early-Stage and Operable Non-small Cell Lung Cancer Treatment: Current Practice and Future Perspectives

Dear Colleagues,

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the U.S. and globally. Over the last decade, however, incidence-based mortality rates have declined at accelerated rates, not only due to efforts in screening for detection of early-stage disease, but also due to remarkable advances in the treatment of metastatic NSCLC. These include the approval of checkpoint inhibitors and a variety of targeted therapies which require comprehensive biomarker testing.

Over the last 5 years, a multitude of clinical trials investigating the role of such therapies for the improvement of long-term survival of operable patients has come to fruition. With the approval of targeted therapy and checkpoint inhibitors, a fast-paced change in the standard of care has demanded an integrated and effective multidisciplinary care of patients with operable NSCLC.

This Special Issue will include narrative reviews on the current treatment, as well as future perspectives for the management of early-stage and operable patients with NSCLC, encompassing biomarker testing, advances in systemic therapy and surgical treatment, and their early rehabilitation.

Dr. Francisco Aécio Almeida
Dr. Debora S. Bruno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• non-small cell lung cancer
• biomarker testing
• checkpoint inhibitors
• perioperative therapy
• targeted therapy
• next-generation sequencing
• radiation therapy
• pulmonary rehabilitation in NSCLC